Genitourinary Cancer

Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney Cancer

June 11, 2021

While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.

Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment

June 09, 2021

Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.

Drug Combo Improves PFS in mCRPC

May 03, 2021

The novel oral TKI masitinib in combination with docetaxel and prednisone resulted in improved progression-free survival compared with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, meeting the predefined primary end point of the phase 2b/3 AB12003 trial.

Adjuvant Nivolumab Granted Priority Review for Muscle-Invasive Urothelial Carcinoma

May 02, 2021

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab for use as an adjuvant treatment in patients with surgically resected, high-risk, muscle-invasive urothelial carcinoma.